Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Cash from Financing Activities

Rigel Pharmaceuticals Cash from Financing Activities Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Cash from Financing Activities from 2010 to 2020.
  • Rigel Pharmaceuticals Cash from Financing Activities for the quarter ending June 06, 2020 was $11m a 6.82% increase of 1m year over year
  • Rigel Pharmaceuticals Cash from Financing Activities for the last 12 months ending June 06, 2020 was $22m a 47.33% increase of 11m year over year
  • Rigel Pharmaceuticals Annual Cash from Financing Activities for 2019 was $11m a -532.59% decrease of -61m from 2018
  • Rigel Pharmaceuticals Annual Cash from Financing Activities for 2018 was $72m a -63.70% decrease of -46m from 2017
  • Rigel Pharmaceuticals Annual Cash from Financing Activities for 2017 was $118m a 78.60% increase of 93m from 2016
Other Cash Flow Metrics:
  • Rigel Pharmaceuticals Cash Flow from Operations for the quarter ending December 12, 2018 was $12m a 300.91% increase of 35m year over year
  • Rigel Pharmaceuticals Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $1m a 1,495.75% increase of 15m year over year
  • Rigel Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $5m a 26.33% increase of 1m year over year
View Chart On Koyfin

Quarterly RIGL Cash from Financing Activities Data

06/2020$11m
03/2020$1m
12/2019$1m
09/2019$10m
06/2019$1m
03/2019$0m
12/2018$1m
09/2018$1m
06/2018$68m
03/2018$2m

Annual RIGL Cash from Financing Activities Data

2019$11m
2018$72m
2017$118m
2016$25m
2015$7m
2014$1m
2013$1m
2012$139m
2011$142m
2010$1m